NCT05806502View on ClinicalTrials.gov

Arginase Inhibition in Type 1 and Type 2 Diabetes Mellitus

NACompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 1, 2018

Primary Completion Date

April 30, 2023

Study Completion Date

April 30, 2023

Conditions
Type 1 DiabetesType 2 Diabetes
Interventions
DIAGNOSTIC_TEST

Nω-hydroxy-nor-arginine

Arginase inhibitor

Trial Locations (1)

17176

Karolinska Institutet, Stockholm

All Listed Sponsors
lead

Karolinska Institutet

OTHER

NCT05806502 - Arginase Inhibition in Type 1 and Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter